title: Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir? Authors' reply.
authors.affiliation: Department of Chemistry, Stanford University, Stanford, CA, USA.
authors.forename: L
authors.initials: L
authors.lastname: Gao
authors.forename: H N
authors.initials: HN
authors.lastname: Trinh
authors.forename: J
authors.initials: J
authors.lastname: Li
authors.forename: M H
authors.initials: MH
authors.lastname: Nguyen
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D000068698:Tenofovir
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; C413685:entecavir; D006147:Guanine; D000068698:Tenofovir; D000225:Adenine